📊 GRDN Key Takeaways
Is GRDN a Good Investment? Thesis Analysis
Guardian Pharmacy demonstrates strong fundamental positioning with pristine balance sheet (zero debt, $65.6M cash), robust revenue growth (17.9% YoY), and solid free cash flow generation ($86.8M, 6.0% margin). However, net income growth (0.5% YoY) significantly lags revenue expansion, indicating concerning margin compression that requires monitoring.
Guardian shows strong top-line growth and high returns on capital on a debt-free, liquid balance sheet, producing free cash flow above net income thanks to low capex and solid operations. Net income growth lags revenue, indicating margin pressure; sustained cost discipline and mix improvements would unlock operating leverage while preserving cash generation.
Why Buy GRDN? Key Strengths
- Zero long-term debt with $65.6M cash position provides financial flexibility and stability
- Strong free cash flow ($86.8M) and high operating cash flow ($100.3M) exceeds net income, demonstrating quality earnings
- Healthy returns on capital with 22.6% ROE and 11.9% ROA despite thin sector-typical margins
- Robust revenue growth (17.9% YoY) outpaces sector average and indicates market share gains
- Debt-free with solid liquidity and $65.6M cash
- High ROE (22.6%) and ROA (11.9%)
- Robust cash generation (6.0% FCF margin; OCF > NI)
GRDN Investment Risks to Consider
- Severe earnings growth stagnation (0.5% YoY) despite 17.9% revenue growth signals margin compression or operational challenges
- Ultra-thin net margin (3.4%) leaves minimal buffer for cost inflation or competitive pricing pressure
- Pharmacy retail sector faces structural headwinds from pricing regulation and consolidation
- High insider trading activity (23 Form 4 filings) warrants scrutiny of insiders' convictions
- Margin pressure: net income growth (0.5% YoY) trails revenue growth (17.9%)
- OCF buoyed by working-capital timing may normalize
- Thin net margin (3.4%) leaves limited buffer for cost shocks
Key Metrics to Watch
- Gross margin trend and components of margin compression between revenue and net income
- Operating expense growth rate relative to revenue growth
- Free cash flow sustainability and conversion efficiency
- Same-store sales growth and comp store metrics if available
- Operating margin
- OCF/Net income conversion
GRDN Financial Metrics
💡 AI Analyst Insight
Guardian Pharmacy Services, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GRDN Profitability Ratios
GRDN vs Consumer Sector
How Guardian Pharmacy Services, Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GRDN Overvalued or Undervalued?
Based on fundamental analysis, Guardian Pharmacy Services, Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GRDN Balance Sheet & Liquidity
GRDN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Guardian Pharmacy Services, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
GRDN Growth Metrics (YoY)
GRDN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $314.4M | $9.0M | N/A |
| Q2 2025 | $300.0M | N/A | N/A |
| Q1 2025 | $275.4M | $9.4M | N/A |
| Q3 2024 | $262.7M | -$122.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GRDN Capital Allocation
GRDN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Guardian Pharmacy Services, Inc. (CIK: 0001802255)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRDN
What is the AI rating for GRDN?
Guardian Pharmacy Services, Inc. (GRDN) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRDN's key strengths?
Claude: Zero long-term debt with $65.6M cash position provides financial flexibility and stability. Strong free cash flow ($86.8M) and high operating cash flow ($100.3M) exceeds net income, demonstrating quality earnings. ChatGPT: Debt-free with solid liquidity and $65.6M cash. High ROE (22.6%) and ROA (11.9%).
What are the risks of investing in GRDN?
Claude: Severe earnings growth stagnation (0.5% YoY) despite 17.9% revenue growth signals margin compression or operational challenges. Ultra-thin net margin (3.4%) leaves minimal buffer for cost inflation or competitive pricing pressure. ChatGPT: Margin pressure: net income growth (0.5% YoY) trails revenue growth (17.9%). OCF buoyed by working-capital timing may normalize.
What is GRDN's revenue and growth?
Guardian Pharmacy Services, Inc. reported revenue of $1.4B.
Does GRDN pay dividends?
Guardian Pharmacy Services, Inc. does not currently pay dividends.
Where can I find GRDN SEC filings?
Official SEC filings for Guardian Pharmacy Services, Inc. (CIK: 0001802255) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRDN's EPS?
Guardian Pharmacy Services, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRDN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Guardian Pharmacy Services, Inc. has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is GRDN stock overvalued or undervalued?
Valuation metrics for GRDN: ROE of 22.6% (sector avg: 18%), net margin of 3.4% (sector avg: 8%). Higher ROE suggests strong returns relative to peers.
Should I buy GRDN stock in 2026?
Our dual AI analysis gives Guardian Pharmacy Services, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GRDN's free cash flow?
Guardian Pharmacy Services, Inc.'s operating cash flow is $100.3M, with capital expenditures of $13.4M. FCF margin is 6.0%.
How does GRDN compare to other Consumer stocks?
Vs Consumer sector averages: Net margin 3.4% (avg: 8%), ROE 22.6% (avg: 18%), current ratio 1.38 (avg: 1.5).